Abstract A232: In vitro and in vivo activity of NMS-E628 against ALK mutations resistant to Xalkori.-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Abstract A232: In vitro and in vivo activity of NMS-E628 against ALK mutations resistant to Xalkori.

Published:2011-11-12 Issue: Volume: Page:
ISSN:
Container-title:Therapeutic Agents: Small Molecule Kinase Inhibitors
language:
Short-container-title:

Author:

Ardini Elena,Menichincheri Maria,Banfi Patrizia,Saccardo Maria Beatrice,Rusconi Luisa,Avanzi Nilla,Amboldi Nadia,Casero Daniele,Cribioli Sabrina,Isacchi Antonella,Donati Daniele,Pesenti Enrico,Galvani Arturo

Publisher

American Association for Cancer Research

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Population pharmacokinetic analysis of entrectinib in pediatric and adult patients with advanced/metastatic solid tumors: support of new drug application submission;Cancer Chemotherapy and Pharmacology;2021-09-18

2. Precision medicine against ALK-positive non-small cell lung cancer: beyond crizotinib;Medical Oncology;2018-04-17

3. Resistance to ALK Inhibitors;Resistance to Targeted Anti-Cancer Therapeutics;2016

4. ALK inhibitors in non-small cell lung cancer: the latest evidence and developments;Therapeutic Advances in Medical Oncology;2015-12-18

5. Sensitivity to Entrectinib Associated With a Novel LMNA-NTRK1 Gene Fusion in Metastatic Colorectal Cancer;JNCI: Journal of the National Cancer Institute;2015-11-12

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP